Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 27, 2026

Finland Prepaid Card and Digital Wallet Market Intelligence Report 2026-2030: Edenred and ePassi Compete on App-Led Usability While Enfuce Strengthens Modular Card Issuing

View original at globenewswire.com
Finland Prepaid Card and Digital Wallet Market Intelligence Report 2026-2030: Edenred and ePassi Compete on App-Led Usability While Enfuce Strengthens Modular Card Issuing Dublin, Feb…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Paper lunch and culture vouchers will be discontinued with use allowed through 2026

    80% confidence

  • Nordic and Estonia plan to implement offline card payment back-ups, with Finland intending to offer offline options and a national instant-payment platform

    80% confidence

  • The prepaid card and digital wallet market in Finland achieved a CAGR of 11.3% during 2021-2025

    80% confidence

  • The value of contactless payments rose 23% year-over-year to EUR 8.4 billion in Q2 2025

    80% confidence

  • The market is forecast to grow at a CAGR of 6.5% during 2026-2030, expanding from USD 3.79 billion in 2025 to approximately USD 5.25 billion by end of 2030

    80% confidence

  • The Finland prepaid card and digital wallet market is expected to grow by 7.7% on annual basis to reach US$4.08 billion in 2026

    80% confidence

  • The most durable prepaid growth pockets in Finland over the next 2-4 years are expected to remain controlled-spend programs (employee benefits, targeted disbursements) and institutional/regulated use cases

    80% confidence

  • Apple Pay and Google Pay are enabled for benefits spending on Edenred Finland platform

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com